A Phase 2, randomized, double-blind, cross-over study of S-600918 in subjects with refractory/unexplained chronic cough

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223969

Enrollment

Registered

2018-07-06

Start date

2018-08-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory/unexplained chronic cough

Interventions

investigational material(s) Generic name etc : S-600918 INN of investigational material : sivopixant Therapeutic category code : 222 Antitussives Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Main inclusion criteria Subjects with refractory/unexplained chronic cough continuing for 6 months or more

Exclusion criteria

Exclusion criteria: Main exclusion criteria Smokers or subjects who started smoking cessation within the last 6 months or former smokers with a pack/year history greater than 20 pack-years

Design outcomes

Primary

Measure	Time frame
efficacy Rate of change in the number of coughs per hour in the daytime from baseline after administration of S-600918 for 2 weeks	—

Secondary

Measure	Time frame
safety pharmacokinetics Plasma concentrations of S-600918 and its metabolite, Adverse events (AEs), Treatment-related AEs, Clinical laboratory tests, Blood pressure and pulse rate, Electrocardiogram (ECG)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026